ArticleJournal of substance abuse treatment2022
Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms.
Article in Journal of substance abuse treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Patient and provider experiences with opioid use disorder care delivered via telehealth: A systematic mixed-studies review.Drug and alcohol dependence · 2025Pooled it
- Modality and terminology changes for behavioral health service delivery during the COVID-19 pandemic: a systematic review.Frontiers in psychiatry · 2023Pooled it
- Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.Addiction science & clinical practice · 2023Trial
- The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services.Harm reduction journal · 2021Trial
- Providing Mental Health and Substance Use Services to People Released From Custody During the COVID-19 Pandemic: A Qualitative Study of Service Providers.The International journal of health planning and management · 2026Article
- Narrative Review of Opioid Use Disorder Treatment Changes During the COVID-19 Pandemic and Their Impact on American Indian/Alaska Native Communities.Nursing open · 2026Review
- Buprenorphine and Methadone Discontinuation During Pregnancy and the Postpartum Period: A Nationwide Cohort Study.The American journal of psychiatry · 2025Article
- Delivering opioid use disorder treatment among American Indian and Alaska Native adults during the COVID-19 pandemic and beyond: Facilitators and barriers to care.Journal of ethnicity in substance abuse · 2025Article
- Patient and clinician experiences with the implementation of telemedicine and related adaptations in office-based buprenorphine treatment during the COVID-19 pandemic: a qualitative study.Addiction science & clinical practice · 2025Article
- State Medicaid Policies Governing Access to Medications for Opioid Use Disorder (MOUD) and MOUD Treatment Use in a Large Sample of People Who Inject Drugs in 20 U.S. States.Substance use & misuse · 2025Article
- Features of drug addiction treatment programs in Atlantic Canada that help (or not) with access and retention: A qualitative study.PloS one · 2025Article
- Frequency and patterns of substance-induced psychosis in persons with concurrent mental health and substance use disorders during the COVID-19 pandemic: A Norwegian register-based cohort study.European psychiatry : the journal of the Association of European Psychiatrists · 2024Article
- Methadone treatment utilization and overdose trends among Medicaid beneficiaries in New Jersey before and during the COVID-19 pandemic.Journal of substance use and addiction treatment · 2024Article
- Methadone clinic staff perceptions of trauma-informed and patient-centered care: the role of individual staff characteristics.Addiction science & clinical practice · 2024Article
- Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland.Harm reduction journal · 2024Article
- Patient and Clinician Experiences with the Implementation of Telemedicine and Related Adaptations in Office-Based Buprenorphine Treatment During the COVID-19 Pandemic: A Qualitative Study.Research square · 2024Article
- Insufficient Impact: Limited Implementation of Federal Regulatory Changes to Methadone and Buprenorphine Access in Arizona During COVID-19.AJPM focus · 2024Article
- Rural and urban clinician views on COVID-19's impact on substance use treatment for individuals on community supervision in Kentucky.Health & justice · 2024Article
- State guidance and system changes related to COVID-19: Impact on opioid treatment programs.Journal of substance use and addiction treatment · 2024Article
- Navigating addiction treatment during COVID-19: policy insights from state health leaders.Health affairs scholar · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe COVID-19 pandemic led to unprecedented temporary federal and state regulatory flexibilities that rapidly transformed medication for opioid use disorder (MOUD) treatment delivery. This study aimed to understand changes in treatment providers' care during COVID-19, provider experiences with the adaptations, and perceptions of which changes should be sustained long-term.
methodsWe conducted in-depth, semi-structured interviews with 20 New Jersey MOUD providers, purposively sampled to reflect diversity in provider setting, specialty, and other characteristics. Using a rapid analysis approach, we summarized content within interview domains and analyzed domains across participants for recurring concepts and themes.
resultsMOUD treatment practice changes taking place during the COVID-19 pandemic included a rapid shift from in-person care to telehealth, reduction in frequency of toxicology testing and psychosocial/counseling services, and modifications to prescription durations and take-home methadone supplies. Modifications to practice were positively received and reinforced a sense of autonomy for providers as well as enhancing the ability to provide patient-centered care. All respondents expressed support for making temporary regulatory flexibilities permanent, but differed in their implementation of the flexibilities and the extent to which they planned to modify their own practices long-term.
conclusionFindings support sustaining temporary regulatory and payment changes to MOUD practice, which may have improved treatment access and allowed for more flexible, individually tailored patient care. Few negative, unintended consequences were reported by providers, but more research is needed to evaluate the patient experience with changes to practice during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.